Citadel Advisors’s ABVC BioPharma ABVC Stock Holding History

Citadel Advisors’s Portfolio ABVC Stock Details ABVC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$114K	Buy	+72,091	New	+$89.8K	﹤0.01%	12593
2026 Q1	–	Sell	-55,543	Closed	-$118K	–	12864
2025 Q4	$118K	Buy	55,543 +39,879	+255%	+$107K	﹤0.01%	11506
2025 Q3	$47.6K	Buy	+15,664	New	+$48.1K	﹤0.01%	12233
2025 Q1	–	Sell	-40,743	Closed	-$24K	–	14366
2024 Q4	$24K	Buy	+40,743	New	+$22.7K	﹤0.01%	13053
2024 Q3	–	Sell	-25,212	Closed	-$19.5K	–	14122
2024 Q2	$19.5K	Buy	+25,212	New	+$25.9K	﹤0.01%	12666
2024 Q1	–	Sell	-27,158	Closed	-$31.5K	–	14466
2023 Q4	$31.5K	Buy	27,158 +11,567	+74%	+$13.6K	﹤0.01%	12226
2023 Q3	$16.2K	Buy	+15,591	New	+$37.7K	﹤0.01%	12786
2022 Q4	–	Sell	-1,261	Closed	-$11K	–	14817
2022 Q3	$11K	Buy	+1,261	New	+$10.6K	﹤0.01%	12248

Other funds holding ABVC

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Vanguard Fiduciary Trust Malvern, Pennsylvania $454B AUM

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $7.72B AUM 32.88% 1-Year Est. Return

PAM

Panagora Asset Management Boston, Massachusetts $32.6B AUM 52.29% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Citadel Advisors's ABVC Position: Q2 2026 in Review

Citadel Advisors opened a new position in ABVC BioPharma (ABVC) in Q2 2026: 72,091 shares worth $114K. The stake represents ﹤0.01% of the portfolio and ranks #12593 among its holdings. This is a return to the name: Citadel Advisors previously reported a position in ABVC as recently as Q4 2025.

Citadel Advisors first reported a position in ABVC in Q3 2022 and has held it in 8 quarters since. The position peaked at $118K in Q4 2025. 15 funds tracked by Wall St. Rank hold ABVC as of Q2 2026.

Citadel Advisors held 72,091 shares of ABVC BioPharma worth $114K as of Q2 2026.
ABVC BioPharma was a new Citadel Advisors position in Q2 2026.
ABVC BioPharma made up ﹤0.01% of Citadel Advisors's portfolio in Q2 2026, its #12593 holding.
Citadel Advisors first reported a position in ABVC BioPharma in Q3 2022 and has held it in 8 quarters since.
Citadel Advisors's ABVC BioPharma position peaked at $118K in Q4 2025.
15 funds tracked by Wall St. Rank held ABVC BioPharma as of Q2 2026.

Based on Citadel Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.